QuidelOrtho Corporation shares fall 3.99% intraday after announcing new diagnostic assays with BUHLMANN Laboratories.

QuidelOrtho Corporation declined 3.99% intraday, with the company announcing the availability of the BUHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems as an MPA. The fCAL turbo assay aids in the diagnosis of inflammatory bowel disease (IBD) and its differentiation from irritable bowel syndrome, while the fPELA turbo assay helps determine pancreatic insufficiency. This collaboration addresses key healthcare trends, including the rise of non-invasive diagnostic tools and the growing focus on gastrointestinal and pancreatic health.